Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

GSK's CD96 candidate GSK'608 is in phase 1 testing, while PVRIG drug GSK'562 is in preclinical development. Under the terms of the deal, GSK gets rights to co-commercialise the TIGIT antibody in ...

The failure of Roche's tiragolumab in the SKYSCRAPER-01 trial in on-small cell lung cancer (NSCLC) has cast a pall over the TIGIT class, but iTeos said it is committed with GSK to completing their ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Pharmaceutical share prices fell last Monday, after US President Donald Trump vowed to reduce drug prices in the USA by as ...

GSK said combinations of its blood-cancer treatment, Blenrep, have been approved by Japan’s Ministry of Health, and that it expects more approvals through the year. The U.K. pharma company said ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more ...